Verseon Corporation
47071 Bayside Pkwy
Fremont
California
94538
United States
Tel: 510-225-9000
Fax: 510-225-9001
Website: https://www.verseon.com/
Email: info@verseon.com
30 articles about Verseon Corporation
-
Verseon To Showcase Low Bleeding Risk Anticoagulation Candidates At BIO-Europe Spring
3/20/2017
-
Verseon Granted U.S. Patents Covering Its Novel Serine Protease Inhibitors
1/4/2017
-
Further Research Confirms That Verseon’s New Class Of Anticoagulants Reduce Bleeding Risk Compared To NOACs By Preserving Platelet Function
12/8/2016
-
Further Research Confirms That Verseon’s New Class Of Anticoagulants Reduce Bleeding Risk Compared To NOACs By Preserving Platelet Function
12/7/2016
-
Research To Be Presented At ASH Annual Meeting Shows Verseon’s New Class Of Anticoagulants Prevents Thrombosis While Preserving Platelet Function
11/28/2016
-
BIO2016: Verseon Reveals More Details On Its Family Of Anti-Coagulants At BIO 2016 International Convention
6/6/2016
-
Verseon Presents Further Trial Data On The Low Bleeding Risk Of Its Family Of Preclinical Anti-Coagulant Drugs At BioEurope Conference
4/11/2016
-
Verseon Final Results And Good Progress On New Family Of Anti-Coagulants
3/9/2016
-
Verseon To Unveil New Preclinical Results For Novel Class Of Oral Anticoagulants At The 3rd International Conference On Heart & Brain
2/10/2016
-
Verseon Presents Data On A New Class Of Anti-Coagulants At The 8th Biotech Showcase Conference
1/13/2016